Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a recent licensing agreement ensuring accelerated access to countries in need.

THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission.

The WHO recommends lenacapavir, an HIV prevention drug, as global funding cuts threaten efforts to combat the epidemic. Learn about its impact and challenges.

Thousands of Kenyans are set to benefit from the roll-out of Lenacapavir injectable HIV preventive drug. The drug is the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated ...